Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus CYCLOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus CYCLOCORT.
ALA-SCALP vs CYCLOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Topical application of a 5% solution to the scalp twice daily.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid